# INDIGO (vorasidenib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vorasidenib

> The FDA approved INDIGO (vorasidenib), sponsored by Zenas BioPharma, Inc. (ZBIO), on Aug 2024 for IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | INDIGO (vorasidenib) |
| Codes | AGI881 |
| Sponsor | Zenas BioPharma, Inc. (ZBIO) https://sec-api.dev/companies/zbio/catalysts |
| Indications | idh1- or idh2-mutant grade 2 astrocytoma or oligodendroglioma, idh1- or idh2-mutant grade 2 22 astrocytoma or oligodendroglioma, grade 2 astrocytoma or oligodendroglioma |
| Modality | small_molecule |
| FDA designations | none disclosed |

## Timeline

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma.
- First seen 2025-06-11, last confirmed 2026-01-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-009826): "In August 2024, the U.S. FDA approved Servier Pharmaceutical's vorasidenib for the treatment of IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma following surgery." https://www.sec.gov/Archives/edgar/data/1811063/000119312526009826/d947742dex993.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-298551): "In August 2024, the U.S. FDA approved Servier Pharmaceutical's vorasidenib for the treatment of IDH1- or IDH2-mutant grade 2 astrocytoma or oligodendroglioma following surgery." https://www.sec.gov/Archives/edgar/data/1811063/000119312525298551/d82457dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-284845): "In August 2024, the U.S. FDA approved Servier Pharmaceutical's vorasidenib for the treatment of IDH1- or IDH2-mutant grade 2 22 astrocytoma or oligodendroglioma following surgery." https://www.sec.gov/Archives/edgar/data/1811063/000119312525284845/d845081dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-139164): "In August 2024, the U.S. FDA approved Servier Pharmaceutical's vorasidenib for the treatment of grade 2 astrocytoma or oligodendroglioma following surgery." https://www.sec.gov/Archives/edgar/data/1811063/000119312525139164/d932856dex991.htm

### February 5, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-02-05, last confirmed 2025-02-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-009368): "Forward-looking statements include, but are not limited to, statements concerning Zenas's plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting INDIGO trial topline results, the 12-week primary endpoint data for the MoonStone trial and the anticipated timing of completing enrollment and reporting topline results for the SunStone trial; its growth strategy; the Company's preliminary unaudited cash, cash equivalents and short-term investments as of December 31," https://www.sec.gov/Archives/edgar/data/1953926/000110465925009368/tm255498d1_ex99-1.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2024-11-12, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-097663): "Target enrollment of the INDIGO trial concluded in November 2024, and Zenas expects to report topline results around year-end 2025." https://www.sec.gov/Archives/edgar/data/1953926/000110465925097663/tm2528075d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-048948): "In the fourth quarter of 2024, Zenas completed the target enrollment of the INDIGO trial and expects to report topline results from the INDIGO trial around year-end 2025." https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116346): "With the completion of targeted enrollment for the largest clinical trial ever conducted in this patient population, the Company expects to report topline results for INDIGO by the end of 2025." https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-076464): "Target enrollment of the INDIGO trial concluded in November 2024, and Zenas expects to report topline results around year-end 2025." https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116346): ""With the achievement of targeted enrollment for INDIGO, the largest IgG4-RD clinical trial ever conducted, we expect to report topline results for this registration-directed study by the end of 2025."" https://www.sec.gov/Archives/edgar/data/1953926/000110465924116346/tm2427736d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-25-109753): "In the fourth quarter of 2024, we completed the target enrollment of the INDIGO trial and expect to report topline results from the INDIGO trial around year-end 2025." https://www.sec.gov/Archives/edgar/data/1953926/000110465925109753/zbio-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011147): "In the fourth quarter of 2024, we completed the target enrollment of the INDIGO trial and expect to report topline results from the INDIGO trial around year-end 2025." https://www.sec.gov/Archives/edgar/data/1953926/000155837025011147/zbio-20250630x10q.htm
- SEC Form 10-K (accession 0001558370-25-002631): "We expect to report topline data from our INDIGO Trial year end 2025 and, subject to the data, submit a biologics license application ("BLA") in 2026." https://www.sec.gov/Archives/edgar/data/1953926/000155837025002631/zbio-20241231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-076464): "- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465925076464/tm2523154d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-048948): "- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -" https://www.sec.gov/Archives/edgar/data/1953926/000110465925048948/tm2514981d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-009368): "-Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025-" https://www.sec.gov/Archives/edgar/data/1953926/000110465925009368/tm255498d1_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vorasidenib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INDIGO (vorasidenib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vorasidenib

```bibtex
@misc{secapidev_pdufa_vorasidenib_20261116,
  title        = {INDIGO (vorasidenib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vorasidenib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vorasidenib_20261116","title":"INDIGO (vorasidenib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vorasidenib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
